The short version of melanocortin agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-22. Anything still debated is marked as such rather than presented as settled.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
. This is consistent with a normal kinetic isotope effect in which the product is slightly depleted in a heavy isotope relative to the reactant. If the isotope effect is small, as is typical for C and N,
== Organisational factors == The apartheid government immediately rejected the argument that the uprising was the spontaneous result of residents' political and socioeconomic grievances and instead claimed consistently that it had been orchestrated by organisations with ulterior – and insurrectionary – political motives. This was apparent as early as 6 September 1984, when Minister of Law and Order Louis le Grange, making a tour of the Vaal townships in an armoured vehicle, denied that the violence was about rent increases and said, "There are individuals and other forces and organisations very clearly behind what is happening in the Vaal Triangle".
UDP-N-acetyl-D-glucosamine + [protein]-L-serine → UDP + [protein]-3-O-(N-acetyl-D-glucosaminyl)-L-serine UDP-N-acetyl-D-glucosamine + [protein]-L-threonine → UDP + [protein]-3-O-(N-acetyl-D-glucosaminyl)-L-threonine First, the hydroxyl group of serine is deprotonated by histidine 498, a catalytic base in this proposed reaction. Lysine 842 is also present to stabilize the UDP moiety. The oxygen ion then attacks the sugar-phosphate bond between the glucosamine and UDP. This results in the splitting of UDP-N-acetylglucosamine into N-acetylglucosamine – peptide and UDP. Proton transfers take place at the phosphate and histidine 498. This mechanism is spurred by OGT gene containing O-linked N-acetylglucosamine transferase. Aside from proton transfers the reaction proceeds in one step, as shown in Figure 2. Figure 2 uses a lone serine residue as a representative of the peptide with a reactive hydroxyl group. Threonine could have also been used in the mechanism.
Blood PFAS levels have been shown to decline when direct contact ceases. PFOA and PFOS levels have declined in U.S. and European fluorochemical workers due to improved facilities, increased usage of personal protective equipment, and the discontinuation of these chemicals from production. Occupational exposure to PFAS in manufacturing continues to be an active area of study in China with numerous investigations linking worker exposure to various PFAS.
Sources: en.wikipedia.org
== Chromatography == One of the main reasons to use response factors is to compensate for the irreproducibility of manual injections into a gas chromatograph (GC). Injection volumes for GCs can be 1 microliter (μL) or less and are difficult to reproduce. Differences in the volume of injected analyte leads to differences in the areas of the peaks in the chromatogram and any quantitative results are suspect. To compensate for this error, a known amount of an internal standard (a second compound that does not interfere with the analysis of the primary analyte) is added to all solutions (standards and unknowns). This way if the injection volumes (and hence the peak areas) differ slightly, the ratio of the areas of the analyte and the internal standard will remain constant from one run to the next. This comparison of runs also applies to solutions with different concentrations of the analyte. The area of the internal standard becomes the value to which all other areas are referenced. Below is the mathematical derivation and application of this method. Consider an analysis of octane (C8H18) using nonane (C9H20) as the internal standard. The 3 chromatograms below are for 3 different samples.
==== Physical activity ==== Physical exercise can improve mental and physical health. Playing sports, walking, cycling, or doing any form of physical activity trigger the production of various hormones, sometimes including endorphins, which can elevate a person's mood. Studies have shown that in some cases, physical activity can have the same impact as antidepressants when treating depression and anxiety. Moreover, cessation of physical exercise may have adverse effects on some mental health conditions, such as depression and anxiety. This could lead to different negative outcomes such as obesity, skewed body image and many health risks associated with mental illnesses. Exercise can improve mental health but it should not be used as an alternative to therapy.
For the crimes of rape, sodomy, and polygamy (the last removed from a later version), the punishment was to be castration for men or rhinotomy for women. For intentional maiming, the bill specified literal eye for an eye retribution. The bill never passed, due to the combination of its perceived barbarity in some parts and perceived leniency in others. In England, the Offences within the Court Act 1541 provided for cutting off a hand as punishment for striking someone inside a courtroom. Thomas Jefferson's punishments revision bill also intended to repeal this. The punishment was abolished in England and Wales by the Offences Against the Person Act 1828. As of 2021, this form of punishment is controversial, as most modern cultures consider it to be morally abhorrent, as it has the effect of permanently disabling a person and constitutes torture. It is thus seen as grossly disproportionate for crimes less than those such as murder.
Haemovigilance – incident management, investigation, follow-up, and reporting Risk management including writing, implementing, updating and monitoring local policies and procedures Blood management education Monitoring and providing feedback on activities related to compliance with best practice guidelines including auditing Change management activities Appropriate use and management including waste minimisation Assisting with the implementation of PBM strategies
=== Graphene superlattices === Periodically stacked graphene and its insulating isomorph provide a fascinating structural element in implementing highly functional superlattices at the atomic scale, which offers possibilities for designing nanoelectronic and photonic devices. Various types of superlattices can be obtained by stacking graphene and its related forms. The energy band in layer-stacked superlattices is found to be more sensitive to the barrier width than that in conventional III–V semiconductor superlattices. When adding more than one atomic layer to the barrier in each period, the coupling of electronic wavefunctions in neighboring potential wells can be significantly reduced, which leads to the degeneration of continuous subbands into quantized energy levels. When varying the well width, the energy levels in the potential wells along the L-M direction behave distinctly from those along the K-H direction. A superlattice corresponds to a periodic or quasi-periodic arrangement of different materials and can be described by a superlattice period which confers a new translational symmetry to the system, impacting their phonon dispersions and subsequently their thermal transport properties. Recently, uniform monolayer graphene-hBN structures have been successfully synthesized via lithography patterning coupled with chemical vapor deposition (CVD). Furthermore, superlattices of graphene-HBN are ideal model systems for the realization and understanding of coherent (wave-like) and incoherent (particle-like) phonon thermal transport.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.